Relay Therapeutics Inc. (RLAY)
Relay Therapeutics Statistics
Share Statistics
Relay Therapeutics has 170.49M shares outstanding. The number of shares has increased by 27.71% in one year.
| Shares Outstanding | 170.49M |
| Shares Change (YoY) | 27.71% |
| Shares Change (QoQ) | 1.28% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 128.5M |
| Failed to Deliver (FTD) Shares | 2.14K |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 18.36M, so 10.77% of the outstanding shares have been sold short.
| Short Interest | 18.36M |
| Short % of Shares Out | 10.77% |
| Short % of Float | 13.1% |
| Short Ratio (days to cover) | 5.48 |
Valuation Ratios
The PE ratio is -1.74 and the forward PE ratio is -1.43. Relay Therapeutics's PEG ratio is 0.11.
| PE Ratio | -1.74 |
| Forward PE | -1.43 |
| PS Ratio | 58.82 |
| Forward PS | 2 |
| PB Ratio | 0.76 |
| P/FCF Ratio | -2.34 |
| PEG Ratio | 0.11 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Relay Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.95, with a Debt / Equity ratio of 0.06.
| Current Ratio | 15.95 |
| Quick Ratio | 15.95 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.13 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $38.34K |
| Profits Per Employee | $-1.29M |
| Employee Count | 261 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -53.25% in the last 52 weeks. The beta is 1.7, so Relay Therapeutics's price volatility has been higher than the market average.
| Beta | 1.7 |
| 52-Week Price Change | -53.25% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 5.25 |
| Relative Strength Index (RSI) | 59.88 |
| Average Volume (20 Days) | 2.34M |
Income Statement
In the last 12 months, Relay Therapeutics had revenue of 10.01M and earned -337.71M in profits. Earnings per share was -2.36.
| Revenue | 10.01M |
| Gross Profit | 10.01M |
| Operating Income | -372.47M |
| Net Income | -337.71M |
| EBITDA | -380.21M |
| EBIT | -385.67M |
| Earnings Per Share (EPS) | -2.36 |
Balance Sheet
The company has 124.29M in cash and 48.5M in debt, giving a net cash position of 75.78M.
| Cash & Cash Equivalents | 124.29M |
| Total Debt | 48.5M |
| Net Cash | 75.78M |
| Retained Earnings | -1.74B |
| Total Assets | 871.3M |
| Working Capital | 758.48M |
Cash Flow
In the last 12 months, operating cash flow was -249.11M and capital expenditures -2.02M, giving a free cash flow of -251.13M.
| Operating Cash Flow | -249.11M |
| Capital Expenditures | -2.02M |
| Free Cash Flow | -251.13M |
| FCF Per Share | -1.76 |
Margins
Gross margin is 100%, with operating and profit margins of -3722.07% and -3374.72%.
| Gross Margin | 100% |
| Operating Margin | -3722.07% |
| Pretax Margin | -3374.72% |
| Profit Margin | -3374.72% |
| EBITDA Margin | -3799.44% |
| EBIT Margin | -3722.07% |
| FCF Margin | -2509.49% |
Dividends & Yields
RLAY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RLAY is $18, which is 443.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $18 |
| Price Target Difference | 443.8% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 0.35 |
| Piotroski F-Score | 1 |